Viramed Biotech AG c/o Dr. Barry Menefee Viralab, Inc. 1730 S. Ditmar Street Oceanside, CA 92054

Re: k092693 Trade/Device Name: Borrelia B31 IgG ViraStripe Regulation Number: 21 CFR 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: Class II Product Code: LSR Dated: August 31, 2009 Received: September 2, 2009

Dear Dr. Barry Menefee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Tile 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

Page 2

notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html. Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

![](images/00169db76f8f19b1799cd6c84d005b18556c752e110cc2bd305054a991924534.jpg)

Enclosure

# Indications for Use Statement

510(k) Number K092693

Device Name: Borrelia B31 IgG ViraStripe®

The Viramed Biotech AG Borrelia B31 IgG ViraStripe®is an in viro qualitative assay or the detection f IgG antibodies to Borrelia burgdorferi in human serum. It is intended for use in the testing of human serum saples which have been found positive or equivocal using an EIA or IFA test procedure r B.burdorferi antibodies. Positive results from this line blot assay are supportive evidence of infection with $B .$ burgdorferi, the causative agent for Lyme discase. The Viramcd Biotech AG Borrelia B31 IgG ViraStripe® can be used aytme ateronset  symptos provided theElA or IFA are positive or equivocal. It should also be usd for folow-up when: 1)Only IgM antibodies were found positive in an line blot assay or Western blot, 2) lG atbies were found by lne blotrWestern blot but were ot considered snificant by the DC crit or a poitive gG Western blot, previously tested sero-negative individuals rehown developantibodis by an EIA or IFA test. The Viramed Biotech AG Borrelia B3I ViraStripe has not been studied in pediatric or adolescent patients.